Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.04B P/E - EPS this Y 17.40% Ern Qtrly Grth -
Income -192.41M Forward P/E -6.08 EPS next Y 0.50% 50D Avg Chg 3.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 3.00%
Dividend N/A Price/Book 5.51 EPS next 5Y - 52W High Chg -31.00%
Recommedations 1.80 Quick Ratio 6.96 Shares Outstanding 95.61M 52W Low Chg 30.00%
Insider Own 0.14% ROA -42.36% Shares Float 73.76M Beta -0.08
Inst Own 100.14% ROE -74.94% Shares Shorted/Prior 12.47M/9.63M Price 12.52
Gross Margin - Profit Margin - Avg. Volume 692,954 Target Price 16.70
Oper. Margin - Earnings Date May 7 Volume 817,742 Change -6.15%
About Cogent Biosciences, Inc.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Cogent Biosciences, Inc. News
04/09/24 Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
02/28/24 COGT Reports Full Year 2023 Financial Results and Business Highlights
08:00 AM Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
02/22/24 Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
02/14/24 Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
02/05/24 Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
01/09/24 Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
01/02/24 Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
12/11/23 Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
12/09/23 Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
12/07/23 Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium
12/04/23 Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting
11/29/23 Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
11/27/23 Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Deliver On Growth Plans?
11/02/23 Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
10/14/23 Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
08/13/23 After losing 15% in the past year, Cogent Biosciences, Inc. (NASDAQ:COGT) institutional owners must be relieved by the recent gain
08/08/23 Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
07/10/23 Analysts Say These 2 Stocks Are Their ‘Top Picks’ for the Rest of 2023
06/09/23 Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock
COGT Chatroom

User Image mimiwor Posted - 1 day ago

$COGT starting my pos...

User Image Stock_Titan Posted - 2 weeks ago

$COGT Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor https://www.stocktitan.net/news/COGT/cogent-biosciences-presents-data-highlighting-potential-best-in-4ugi6ynzoixi.html

User Image DonCorleone77 Posted - 03/29/24

$COGT Cogent Biosciences files to sell 31.2M shares of common stock for holders

User Image StockConsultant Posted - 1 month ago

$COGT Cogent Biosciences stock good day off support, from Stocks To Watch , see https://stockconsultant.com/?COGT

User Image Javier1973 Posted - 1 month ago

$COGT hijos de pppp…..

User Image Javier1973 Posted - 1 month ago

$COGT cabrooonessssss

User Image Javier1973 Posted - 02/29/24

$COGT que hijos de puta

User Image Atrain1189 Posted - 02/28/24

$COGT any near term catalysts? After that data recently does this just go without PR for a long time?

User Image Javier1973 Posted - 02/28/24

$COGT joderrrrrputa mierda

User Image Thestocktraderhubzee Posted - 02/28/24

WATCHLIST FEB 28 2024.. $FRPT JP Morgan Maintains Neutral on Freshpet, Raises Price Target to $102 $EDIT JP Morgan Maintains Neutral on Editas Medicine, Raises Price Target to $9 $COGT JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $20 $PPBT HC Wainwright & Co. Reiterates Buy on Purple Biotech, Maintains $10 Price Target $WDAY Citigroup Maintains Neutral on Workday, Raises Price Target to $293

User Image Thestocktraderhubzee Posted - 02/27/24

WATCHLIST FEB 27 2024. $GFI Scotiabank Maintains Sector Perform on Gold Fields, Lowers Price Target to $15 $GENI Cantor Fitzgerald Reiterates Overweight on Genius Sports, Maintains $8 Price Target $COGT Citigroup Maintains Buy on Cogent Biosciences, Raises Price Target to $13 $CRM Citigroup Maintains Neutral on Salesforce, Raises Price Target to $325 $MDGL B. Riley Securities Downgrades Madrigal Pharmaceuticals to Sell, Announces $155 Price Target

User Image Leoniski Posted - 2 months ago

$COGT

User Image epsguid Posted - 2 months ago

$COGT reported a loss of $0.63, consensus was ($0.54) via @eWhispers #epsmiss http://eps.sh/d/cogt

User Image DonCorleone77 Posted - 2 months ago

$COGT Cogent Biosciences expects cash to fund requirements into 2027 As of December 31, 2023, Cogent had cash, cash equivalents and marketable securities of $273.2 million. Cogent believes this year-end balance, together with the gross proceeds from the $225.0 million oversubscribed private placement, which closed February 16, 2024, will be sufficient to fund its operating expenses and capital expenditure requirements into 2027, including through clinical readouts from the ongoing SUMMIT, PEAK and APEX registration-directed trials.

User Image DonCorleone77 Posted - 2 months ago

$COGT Cogent Biosciences reports Q4 EPS (63c), consensus (55c) "We have entered 2024 in a very strong position," said Andrew Robbins, Cogent's President and Chief Executive Officer. "We are now actively enrolling three registration-directed clinical trials of bezuclastinib across NonAdvSM, AdvSM and 2nd-line GIST patients, all of which are on track to deliver top-line results in 2025. With our recent fundraising, we are funded into 2027, and based on the clinical data we have presented across these programs to date, believe strongly that bezuclastinib has the opportunity to become the best-in-class KIT mutant inhibitor for these three indications."

User Image Stock_Titan Posted - 2 months ago

$COGT Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results https://www.stocktitan.net/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-fourth-nsf1rdlps9gl.html

User Image Manipulation13F Posted - 2 months ago

$COGT Nice dip buy for me 👀

User Image Leoniski Posted - 2 months ago

$ZVSA $COGT with significant good news. Float held by institutional investors 112% according to Yahoo. This is heavily shorted and a good short squeeze candidate IMHO.

User Image BugHunti Posted - 2 months ago

$COGT https://finance.yahoo.com/news/steven-cohens-point72-asset-management-081352372.html

User Image Leoniski Posted - 2 months ago

$COGT Need to break that wall really hard and off we go!

User Image u_R_a_bagholder Posted - 2 months ago

$COGT had been waiting for a dip to buy this, in.

User Image Not_Financial_Advice2 Posted - 2 months ago

$ROOT $COGT

User Image Leoniski Posted - 2 months ago

$ROOT $COGT with significant good news. Float held by institutional investors 112% according to Yahoo. This is heavily shorted and a good short squeeze candidate IMHO.

User Image Leoniski Posted - 2 months ago

$PFE $COGT with significant good news. Float held by institutional investors 112% according to Yahoo. This is heavily shorted and a good squeeze candidate IMHO.

User Image Leoniski Posted - 2 months ago

$CVNA $COGT with significant good news. Float held by institutional investors 112% according to Yahoo. This is heavily shorted and a good squeeze candidate IMHO.

User Image Leoniski Posted - 2 months ago

$AXTI $COGT with significant good news. Float held by institutional investors 112% according to Yahoo. This is heavily shorted and a good squeeze candidate IMHO.

User Image Leoniski Posted - 2 months ago

$IFBD $COGT with significant good news. Float held by institutional investors 112% according to Yahoo. This is heavily shorted and a good squeeze candidate IMHO.

User Image Leoniski Posted - 2 months ago

$EVH $COGT with significant good news. Float held by institutional investors 112% according to Yahoo. This is heavily shorted and a good squeeze candidate IMHO.

User Image Leoniski Posted - 2 months ago

$LZ $COGT with significant good news. Float held by institutional investors 112% according to Yahoo. This is heavily shorted and a good squeeze candidate IMHO.

User Image Leoniski Posted - 2 months ago

$SQ $COGT with significant good news. Float held by institutional investors 112% according to Yahoo. This is heavily shorted and a good squeeze candidate IMHO.

Analyst Ratings
JP Morgan Overweight Feb 27, 24
Citigroup Buy Feb 26, 24
Baird Neutral Feb 26, 24
Needham Buy Feb 26, 24
Wedbush Neutral Feb 23, 24
Needham Buy Feb 12, 24
Citigroup Buy Feb 8, 24
HC Wainwright & Co. Buy Dec 15, 23
Wedbush Neutral Dec 11, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Fairmount Funds Management LLC - - Jun 16 Buy 8.25 1,200,000 9,900,000 2,472,124 06/21/22